ROIV

Roivant Sciences (ROIV)

Roivant Sciences Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ROIV

1 2 3 4 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/31	10 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/31	05 : 46	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/30	20 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/30	20 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/30	20 : 00	GlobeNewswire Inc.	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/23	10 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/23	10 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/23	10 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/17	05 : 05	GlobeNewswire Inc.	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024	NASDAQ:ROIV	Roivant Sciences Ltd
2024/04/02	20 : 00	GlobeNewswire Inc.	Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million	NASDAQ:ROIV	Roivant Sciences Ltd
2024/03/27	07 : 22	PR Newswire (US)	Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600	NASDAQ:ROIV	Roivant Sciences Ltd
2024/02/13	21 : 00	GlobeNewswire Inc.	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update	NASDAQ:ROIV	Roivant Sciences Ltd
2024/01/31	06 : 05	GlobeNewswire Inc.	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024	NASDAQ:ROIV	Roivant Sciences Ltd
2023/12/21	06 : 30	GlobeNewswire Inc.	Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease	NASDAQ:ROIV	Roivant Sciences Ltd
2023/12/14	23 : 00	GlobeNewswire Inc.	Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease	NASDAQ:ROIV	Roivant Sciences Ltd
2023/11/28	21 : 00	GlobeNewswire Inc.	Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential	NASDAQ:ROIV	Roivant Sciences Ltd
2023/11/27	22 : 00	GlobeNewswire Inc.	Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus	NASDAQ:ROIV	Roivant Sciences Ltd
2023/11/13	21 : 00	GlobeNewswire Inc.	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update	NASDAQ:ROIV	Roivant Sciences Ltd
2023/11/10	22 : 00	GlobeNewswire Inc.	Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors	NASDAQ:ROIV	Roivant Sciences Ltd
2023/10/31	06 : 30	GlobeNewswire Inc.	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023	NASDAQ:ROIV	Roivant Sciences Ltd
2023/10/24	04 : 41	Dow Jones News	Trending: Roche to Buy Telavant From Roivant and Pfizer	NASDAQ:ROIV	Roivant Sciences Ltd
2023/10/23	20 : 18	IH Market News	Monday’s Wall Street Highlights: Philips, Chevron, Textainer, Okta, Roivant, and more	NASDAQ:ROIV	Roivant Sciences Ltd
2023/10/23	17 : 16	Dow Jones News	Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion -- Update	NASDAQ:ROIV	Roivant Sciences Ltd
2023/10/23	14 : 50	Dow Jones News	Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Billion Deal	NASDAQ:ROIV	Roivant Sciences Ltd
2023/10/23	14 : 00	GlobeNewswire Inc.	Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant	NASDAQ:ROIV	Roivant Sciences Ltd
2023/10/13	21 : 00	GlobeNewswire Inc.	Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer	NASDAQ:ROIV	Roivant Sciences Ltd
2023/09/26	19 : 00	GlobeNewswire Inc.	Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results	NASDAQ:ROIV	Roivant Sciences Ltd
2023/09/11	21 : 00	GlobeNewswire Inc.	Roivant Announces Completion of Redemption of its Outstanding Warrants	NASDAQ:ROIV	Roivant Sciences Ltd
2023/08/18	05 : 05	GlobeNewswire Inc.	Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants	NASDAQ:ROIV	Roivant Sciences Ltd
2023/08/14	20 : 00	GlobeNewswire Inc.	Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update	NASDAQ:ROIV	Roivant Sciences Ltd